Cardiological Side Effects of Antipsychotic Agents.
- Published in:
- International Medical Journal, 2025, v. 32, n. 2, p. 69
- By:
- Publication type:
- Article
Works about DRUG therapy for schizophrenia
Results: 1774
1
2
The Importance of Antipsychotic Treatment in Severe Mental Disorders.
- Published in:
- 2025
- By:
- Publication type:
- Editorial
3
Lorazepam challenge test for catatonia.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
4
Clozapine and refractory diabetes treatment.
- Published in:
- Journal of Diabetes Nursing, 2013, v. 17, n. 3, p. 112
- By:
- Publication type:
- Article
5
Mental Health Staff's Perspectives on Tapering of Antipsychotic Medication: A Focus Group Study.
- Published in:
- Qualitative Health Research, 2023, v. 33, n. 13, p. 1165, doi. 10.1177/10497323231195821
- By:
- Publication type:
- Article
6
Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis.
- Published in:
- Qualitative Health Research, 2017, v. 27, n. 4, p. 559, doi. 10.1177/1049732316634047
- By:
- Publication type:
- Article
7
Real‐world usage of paliperidone palmitate injection.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 7, p. 2, doi. 10.1002/pu.31322
- By:
- Publication type:
- Article
8
Your Medication Information.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 6, p. 9, doi. 10.1002/pu.31319
- Publication type:
- Article
9
Study shows improved schizophrenia negative symptoms with xanomeline‐trospium.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 6, p. 8, doi. 10.1002/pu.31318
- Publication type:
- Article
10
Long‐term dopamine receptor blockade not linked to psychotic relapse.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 6, p. 1, doi. 10.1002/pu.31308
- Publication type:
- Article
11
Study suggests benefit of continuing antipsychotic during pregnancy.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 5, p. 6, doi. 10.1002/pu.31303
- Publication type:
- Article
12
Despite adverse event risk, anti psychotic polypharmacy has continued to rise.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 5, p. 1, doi. 10.1002/pu.31298
- Publication type:
- Article
13
Cohort study suggests benefit of earlier initiation of clozapine.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 5, p. 1, doi. 10.1002/pu.31297
- Publication type:
- Article
14
Olanzapine plus samidorphan shows long‐term safety in patients with schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 4, p. 8, doi. 10.1002/pu.31293
- Publication type:
- Article
15
Xanomeline‐trospium significantly improves cognition in acute schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 4, p. 1, doi. 10.1002/pu.31284
- Publication type:
- Article
16
Long‐term antipsychotic use linked to breast cancer risk.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 2, p. 8, doi. 10.1002/pu.31270
- Publication type:
- Article
17
LAI antipsychotics show effective results in comparative analysis.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 2, p. 3, doi. 10.1002/pu.31263
- Publication type:
- Article
18
Quetiapine co‐administration with fluvoxamine and duloxetine.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 2, p. 2, doi. 10.1002/pu.31262
- By:
- Publication type:
- Article
19
Approval.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 1, p. 8, doi. 10.1002/pu.31258
- Publication type:
- Article
20
Switch from antipsychotic polypharmacy to monotherapy reduces side effects.
- Published in:
- Brown University Psychopharmacology Update, 2025, v. 36, n. 1, p. 1, doi. 10.1002/pu.31250
- Publication type:
- Article
21
Study finds increased risk of hematologic malignancy in patients receiving clozapine.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 9, p. 8, doi. 10.1002/pu.31207
- Publication type:
- Article
22
Lipid‐modifying statins, fibrates reduce mortality in schizophrenia patients.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 9, p. 1, doi. 10.1002/pu.31199
- Publication type:
- Article
23
Approval.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 8, p. 8, doi. 10.1002/pu.31196
- Publication type:
- Article
24
Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 8, p. 4, doi. 10.1002/pu.31190
- Publication type:
- Article
25
Data on clozapine‐induced agranulocytosis suggest monitoring could be relaxed.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 8, p. 1, doi. 10.1002/pu.31186
- Publication type:
- Article
26
Antipsychotic effects in randomized trials may not reflect real‐world outcomes.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 6, p. 8, doi. 10.1002/pu.31173
- Publication type:
- Article
27
Xanomeline‐trospium combination shows strong results in schizophrenia trial.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 4, p. 1, doi. 10.1002/pu.31139
- Publication type:
- Article
28
LAI added to clozapine reduces risk of hospitalization.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 3, p. 8, doi. 10.1002/pu.31136
- Publication type:
- Article
29
Clozapine is not the end of the story.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 3, p. 7, doi. 10.1002/pu.31134
- By:
- Publication type:
- Article
30
Your Medication Information.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 2, p. 9, doi. 10.1002/pu.31128
- Publication type:
- Article
31
Subcutaneous version of risperidone delays relapse to schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2024, v. 35, n. 2, p. 6, doi. 10.1002/pu.31121
- Publication type:
- Article
32
Neutropenia and thyroid dysfunction associated with lithium and clozapine therapy.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 11, p. 2, doi. 10.1002/pu.31084
- By:
- Publication type:
- Article
33
Metformin has strongest evidence base for limiting antipsychotic‐induced weight gain in schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 9, p. 8, doi. 10.1002/pu.31064
- Publication type:
- Article
34
Approvals.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 8, p. 8, doi. 10.1002/pu.31055
- Publication type:
- Article
35
Clonidine augmentation reduces negative symptoms in patients with schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 8, p. 7, doi. 10.1002/pu.31050
- Publication type:
- Article
36
Study identifies recommended therapeutic levels for clozapine.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 7, p. 4, doi. 10.1002/pu.31036
- Publication type:
- Article
37
Antipsychotic polypharmacy carries lower risk of hospitalization than monotherapy.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 7, p. 1, doi. 10.1002/pu.31032
- Publication type:
- Article
38
Your Medication Information.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 5, p. 9, doi. 10.1002/pu.31018
- Publication type:
- Article
39
Meta‐analysis: Extended use of most antipsychotics associated with weight gain.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 5, p. 3, doi. 10.1002/pu.31010
- Publication type:
- Article
40
LAI antipsychotics offer little advantage for continuation of treatment.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 5, p. 1, doi. 10.1002/pu.31007
- Publication type:
- Article
41
Phase 1b trial of emraclidine for schizophrenia shows minimal adverse events.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 4, p. 7, doi. 10.1002/pu.31002
- Publication type:
- Article
42
Risperidone dosing schedule.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 4, p. 2, doi. 10.1002/pu.30995
- By:
- Publication type:
- Article
43
Gradual taper of antipsychotics safer in chronic schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 3, p. 8, doi. 10.1002/pu.30990
- Publication type:
- Article
44
Once‐ versus multiple‐daily dosing of clozapine.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 3, p. 2, doi. 10.1002/pu.30984
- By:
- Publication type:
- Article
45
Dexmedetomidine reduces acute agitation in patients with schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 2, p. 8, doi. 10.1002/pu.30980
- Publication type:
- Article
46
Potential cinacalcet‐clozapine interaction.
- Published in:
- Brown University Psychopharmacology Update, 2023, v. 34, n. 1, p. 2, doi. 10.1002/pu.30960
- By:
- Publication type:
- Article
47
Clozapine, antipsychotic polytherapy reduce SUD risk in patients with schizophrenia.
- Published in:
- Brown University Psychopharmacology Update, 2022, v. 33, n. 12, p. 1, doi. 10.1002/pu.30947
- Publication type:
- Article
48
Your Medication Information.
- Published in:
- Brown University Psychopharmacology Update, 2022, v. 33, n. 11, p. 9, doi. 10.1002/pu.30945
- Publication type:
- Article
49
Study finds LAI antipsychotics linked with lower risk of hospitalization.
- Published in:
- Brown University Psychopharmacology Update, 2022, v. 33, n. 11, p. 4, doi. 10.1002/pu.30939
- Publication type:
- Article
50
Clozapine‐induced polyserositis.
- Published in:
- Brown University Psychopharmacology Update, 2022, v. 33, n. 10, p. 2, doi. 10.1002/pu.30925
- Publication type:
- Article